Rubedo Life Sciences Revenue and Competitors

Location

$52M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Rubedo Life Sciences's estimated annual revenue is currently $6M per year.(i)
  • Rubedo Life Sciences's estimated revenue per employee is $155,000
  • Rubedo Life Sciences's total funding is $52M.

Employee Data

  • Rubedo Life Sciences has 39 Employees.(i)
  • Rubedo Life Sciences grew their employee count by 22% last year.

Rubedo Life Sciences's People

NameTitleEmail/Phone
1
Co-Founder & CEOReveal Email/Phone
2
Co-Founder / ScientistReveal Email/Phone
3
Co-Founder, Chairman Chemistry and DevelopmentReveal Email/Phone
4
SVP, DiscoveryReveal Email/Phone
5
Sr. Director, Discovery ResearchReveal Email/Phone
6
Angel InvestorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.3M2131%N/AN/A
Add Company

What Is Rubedo Life Sciences?

Rubedo Life Sciences is an anti-aging company based in the Silicon Valley, California. Rubedo mission is to extend health-span by targeting cell in the body in an accurate and safe way. We aim to remove from the body "bad cells" that drive agin (such as the pro-inflammatory senescent cells), and to improve functions of "good cells (such as stem cells). Rubedo is developing treatments for aged-related diseases such as Alzheimer's, Cancer, Diabetes, or Arthritis. The company is founded and driven by leaders in aging, regenerative medicine, senescence, combinatorial and medicinal chemistry from top academics (such as Stanford, Berkley and Cambridge UK) and top life sciences companies (such as Affymax, Xenoport, Verily).

keywords:N/A

$52M

Total Funding

39

Number of Employees

$6M

Revenue (est)

22%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.6M39-13%N/A
#2
$5.1M39N/AN/A
#3
$9.8M3922%N/A
#4
$8.6M3911%N/A
#5
$6.7M40-33%$20M